We are live on
!
Find out more
RGC
Roberts, Glore & Co Portfolio holdings
AUM
$364M
1-Year Est. Return
19.54%
This Fund
S&P 500
This Quarter
Est. Return
-0.27%
1 Year Est. Return
+19.54%
3 Year Est. Return
+59.43%
5 Year Est. Return
+77.93%
10 Year Est. Return
+273.65%
AUM
$337M
AUM Growth
-$8.73M
(-2.5%)
Cap. Flow
-$4.66M
Cap. Flow
% of AUM
-1.38%
Top 10 Holdings %
Top 10 Hldgs %
36.68%
Holding
216
New
7
Increased
44
Reduced
112
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASML
ASML
|
+$732K |
| 2 |
Elevance Health
ELV
|
+$644K |
| 3 |
Adobe
ADBE
|
+$573K |
| 4 |
Vanguard Morningstar Small-Cap Value ETF
VBR
|
+$510K |
| 5 |
Nike
NKE
|
+$337K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$906K |
| 2 |
Vanguard Tax-Exempt Bond Index Fund
VTEB
|
+$623K |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$587K |
| 4 |
Estee Lauder
EL
|
+$507K |
| 5 |
Global Payments
GPN
|
+$433K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.56% |
| 2 | Healthcare | 15.23% |
| 3 | Financials | 13.1% |
| 4 | Industrials | 8.56% |
| 5 | Communication Services | 7.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
First Solar
FSLR
$22.8B
| $204K | 0.06% |
1,158
| – | – |
|
202
Markel Group
MKL
$23.4B
| $204K | 0.06% |
+118
| New | +$196K |
|
203
Neurocrine Biosciences
NBIX
$16.9B
| $204K | 0.06% |
+1,492
| New | +$185K |
|
204
UFP Industries
UFPI
$4.91B
| $201K | 0.06% |
1,788
| – | – |
|
|
EMF
205
Templeton Emerging Markets Fund
EMF
$317M
| $162K | 0.05% |
13,550
| – | – |
|
206
Warner Bros
WBD
$64.1B
| $158K | 0.05% |
14,964
-2,484
| -14% | -$23.1K |
|
|
JOF
207
Japan Smaller Capitalization Fund
JOF
$320M
| $139K | 0.04% |
18,133
-835
| -4% | -$6.49K |
|
208
Ambev
ABEV
$48.1B
| $63.8K | 0.02% |
34,480
+7,635
| +28% | +$16.9K |
|
209
Advance Auto Parts
AAP
$3.37B
| – | – |
-8,270
| Closed | -$322K |
|
210
Constellation Energy
CEG
$93.4B
| – | – |
-880
| Closed | -$229K |
|
211
Consolidated Edison
ED
$40.4B
| – | – |
-2,000
| Closed | -$208K |
|
|
212
Estee Lauder
EL
$30.5B
| – | – |
-5,082
| Closed | -$507K |
|
213
Fortune Brands Innovations
FBIN
$5.87B
| – | – |
-2,306
| Closed | -$206K |
|
214
Generac Holdings
GNRC
$11.6B
| – | – |
-1,374
| Closed | -$218K |
|
215
Incyte
INCY
$24.2B
| – | – |
-6,300
| Closed | -$416K |
|
|
PCH
216
DELISTED
PotlatchDeltic
PCH
| – | – |
-4,839
| Closed | -$218K |
|
Similar funds
VBFP
EW
RBFC
ACM
DCP
MA
SWA
OAJ
Roberts, Glore & Co's Q4 2024 Portfolio in Review
As of Q4 2024, Roberts, Glore & Co held 216 positions worth $337M, down 2.5% from $346M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Roberts, Glore & Co's Q4 2024 filing shows 7 new, 44 increased, 112 reduced and 8 closed positions. Its largest new stake was ASML: 1,020 shares worth $707K. The largest sale was CVS Health, an estimated $906K.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Roberts, Glore & Co's largest Q4 2024 buy was ASML: 1,020 shares worth $707K.
- Roberts, Glore & Co added most to Elevance Health in Q4 2024, an estimated $644K increase.
- Roberts, Glore & Co's biggest Q4 2024 reduction was CVS Health, cutting an estimated $906K.
- Roberts, Glore & Co fully exited Estee Lauder in Q4 2024, selling an estimated $507K.
- Roberts, Glore & Co's ten largest holdings make up 37% of its $337M portfolio in Q4 2024.
- Roberts, Glore & Co opened 7 new positions and closed 8 in Q4 2024.
- Roberts, Glore & Co's portfolio value fell 2.5% quarter-over-quarter to $337M.
Based on Roberts, Glore & Co's 13F filing for Q4 2024, filed 7 Feb 2025.